- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07832396
Community Study to Increase Mammogram Screening Among Overdue Women (IMPLEMENT)
A Community-Based Implementation Study of Pragmatic Interventions to Improve Mammography Uptake in Non-Screen Adherent Women
Breast cancer is the most common cancer among women in Singapore, and regular mammogram screening can detect breast cancer early when treatment is more effective. However, many eligible women do not attend regular mammogram screening despite national screening programs and free screening for eligible women enrolled in Healthier SG.
The IMPLEMENT Study is a community-based implementation study that will evaluate whether practical, low-cost behavioural interventions can increase mammogram screening among women who are overdue for screening or have never been screened. The interventions have previously been shown to be effective in randomized controlled trials conducted by the study team.
The study will be conducted in the Health District @ Queenstown (HD@QT). Women living in Happy Village @ Mei Ling will receive one behavioural intervention that has been shown to be effective in a previous randomized trial, while eligible women living in the remainder of HD@QT will receive usual care with no study intervention. Different implementation trials will be conducted for different screening populations, including women who have never undergone mammography, women who are overdue for repeat mammography, and women who are due for their next mammogram.
The primary objective is to determine whether implementing these evidence-based interventions in a real-world community setting increases the proportion of women completing mammography within four months. Results from this study will help determine whether these interventions can be integrated into community health programs to improve breast cancer screening participation in Singapore.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Singapore, Singapur
- National University Hospital Singapore
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Singaporean citizen
- Age 50-69 years
- Registered patients of NUHS
- No history of breast cancer
- Eligible for free mammograms (Signed up with Healthier SG with a primary care provider within the NUHS Primary Care Network)
- In each individual trial in this proposed series of trials, the participants will either be:
Repeat screeners: Have undergone a mammogram at least once in the past, but not within the past 2 years Never screeners: Have never done mammogram in the past (no records in EPIC) Active screeners: Have undergone a mammogram within the past 20-24 months but have not scheduled their next screening in Health Appointment System (HAS)
Exclusion Criteria:
- Diagnosis of breast cancer in EPIC
- Pregnant woman
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Evidence-based behavioural intervention
Eligible women residing in Happy Village @ Mei Ling will receive the evidence-based behavioural intervention specified for their screening population. The intervention will be implemented in the community to increase mammography completion within four months. In Trial A on defaulted repeats screeners the intervention will be Mailed Reminder (MR) with dedicated hotline scheduling. In Trial 2 on never-screeners the intervention will be MR with Prescheduled Appointment. |
Evidence-based behavioural intervention delivered to eligible women in Happy Village @ Mei Ling to encourage mammography screening. The specific intervention, delivery method, frequency, and duration will be defined for each screening population based on the corresponding previous randomized trial. In Trial 1 the intervention will be mailed reminder (MR) with dedicated appointment scheduling hotline. In Trial 2, the intervention will be MR with prescheduled appointment. |
|
Kein Eingriff: Comparator group
Eligible women residing in the remainder of HD@QT will receive usual care without the study-delivered behavioural intervention. Mammography completion will be assessed using the same outcome definition and follow-up period. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of eligible women who complete mammography within four months of intervention delivery.
Zeitfenster: 4 month
|
This community-based implementation study will evaluate the effectiveness of evidence-based behavioural interventions to increase mammography screening in eligible women residing in the Health District @ Queenstown. Eligible women living in Happy Village @ Mei Ling will receive the intervention assigned to their screening population, while eligible women living in the remainder of the health district will receive usual care. The study will include implementation cohorts of women who have never undergone mammography, women who are overdue for repeat mammography, and women who are due for their next mammogram. The intervention will be delivered in parallel to usual care, and allocation will be non-randomized based on residential location. Mammography completion will be assessed within four months of intervention delivery. |
4 month
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time from mailed reminder to mammography completion
Zeitfenster: From mailer delivery through 4 months.
|
Time from intervention mailer delivery to completion of mammography, measured in days. |
From mailer delivery through 4 months.
|
|
Time to appointment booking
Zeitfenster: From mailer delivery through 4 months.
|
Time from intervention mailer delivery to the first mammography appointment booking, measured in days. |
From mailer delivery through 4 months.
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Factors associated with mammography completion
Zeitfenster: Baseline participant characteristics; mammography completion assessed within 4 months
|
Exploratory analysis of the association between age, ethnicity, housing type, prior mammography history, and time since last mammogram, and mammography completion. |
Baseline participant characteristics; mammography completion assessed within 4 months
|
|
Mammography appointment no-show rate
Zeitfenster: From first appointment booking through 4 months after mailer delivery.
|
Proportion of booked mammography appointments not attended, among participants with available appointment attendance data. |
From first appointment booking through 4 months after mailer delivery.
|
|
Number of participants attending Happy Village outposts
Zeitfenster: From intervention delivery through 4 months.
|
Number of participants in the implementation group who attend Happy Village outposts for screening-related support or services. |
From intervention delivery through 4 months.
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026-0741
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .